Global Intratumoral Cancer Therapies Market Assessment, By Type of Cancer [Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Head and Neck Cancer, Melanoma, Others], By Technology [Vaccines, Monoclonal Antibodies, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Checkpoint Inhibitors, Cytokines, Others], By End-user [Cancer Research Centers, Specialty Clinics, Hospitals], By Region, Opportunities and Forecast, 2017-2031F
Global intratumoral cancer therapies market is expected to experience significant growth over the forecast period owing to rising research and development activities and strategic collaborations among various market players.
Home>Industry Reports>Global Intratumoral Cancer Therapies Market Assessment, Opportunities and Forecast, 2017-2031F
Global intratumoral cancer therapies market is projected to witness a CAGR of 10.33% during the forecast period 2024-2031, growing from USD 202.67 billion in 2023 to USD 444.82 billion in 2031F. The growing prevalence of cancer in various regions across the globe, expansion of the pharmaceutical industry, and rising research and development activities are bolstering the market growth. As per the American Cancer Society, 1,958,310 new cases and 609,820 deaths related to cancer were estimated to occur in the United States in 2023.
The growing adoption of immunotherapy drugs that can be tailored to the individual requirements of the patients and customized to their genetic profile for improving outcomes is providing lucrative growth opportunities to the market. Increasing research and development activities for investigating the efficacy of mRNA cancer vaccines is further supporting the market expansion. In 2023, a phase 2 clinical trial was opened to investigate whether therapeutic vaccines reduce the risk of return of pancreatic cancer after the removal of tumors by surgery. The study is expected to enroll 260 patients at Memorial Sloan Kettering Cancer Center (MSK) and approximately 80 sites across the globe. The trial will be open to individuals who recently received pancreatic cancer diagnosis and who have not yet had treatments including radiation therapy, immunotherapy, and chemotherapy or surgery. During phase 1 the vaccine was well tolerated by most patients, with phase 2 expected to offer clarity on the vaccine and various potential benefits. The trial is expected to offer insights into whether the mRNA approach performs better as compared to the current standards of the treatment.
Increasing Investments Anticipated to Offer Opportunities
Due to the growing prevalence of cancer in various regions across the globe, several governments are increasing investment in research and development activities for novel treatment solutions. Cancer has a significant economic impact on the lives of the patients and their families as well as the society, therefore there is a strong economic front for investing in various measures that will support the faster treatment and testing of patients. By investing in cancer research, they aim to support early detection of different types of cancers. For 2023, the American Institute for Cancer Research joined One Voice Against Cancer for requesting USD 49 billion in base funding for the National Institutes of Health.
Furthermore, various leading market players are investing in cancer research activities. According to Novartis India MD, the company invests 20% of its revenue towards research activities, including cancer research. With the help of dedicated research activities, the recognition and unraveling of cancer complexities will become much easier.
Strategic Collaborations Support Market Expansion
Through strategic partnerships and collaborations different biotechnology and pharmaceutical companies can pool their resources and expertise to combine their ideas, experience, and knowledge for fast-tracking the development process. In February 2022, BioNTech SE entered a global strategic partnership with Medigene AG to advance TCR-based immunotherapies against cancer. The research collaboration is expected to encompass several target structures. BioNTech SE is expected to hold exclusive worldwide commercialization rights and will be responsible for developing TCR therapies that result from the collaboration.
Amgen Inc., one of the leading American multinational biopharmaceutical companies committed to easing patient suffering by manufacturing, delivering, discovering, and developing innovative human therapeutics launched Amgen Partners of Choice. The network aims to bring together the company’s clinical leaders and research and development experts from eight research centers around the globe. The network expects to create various collaboration channels to expedite the transformational programs that are focused on selected tumor types and disease areas.
North America Accounts for Significant Market Share
The strong presence of various leading market players, the increasing prevalence of cancer in the region, and rising investments in research and development activities are supporting the expansion of the market in the region. According to the Canadian Cancer Society, it was estimated that there would be 239,100 new cancer cases and 86,700 cancer-related deaths in Canada in 2023. Increasing public-private research collaborations are expected to offer the advancement of new therapies, supporting the market expansion in North America. For instance, the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration, is expected to facilitate uniform and systemic clinical testing of biomarkers for advancing the understanding of resistance to immunotherapies and mechanisms of treatment response.
Meanwhile, Europe is expected to witness significant growth in the coming years. The growth can be attributed to the rising research and development activities by the regional market players. Sanofi is conducting an interventional study to determine maximum administered dose or maximum tolerated dose and tolerability and safety of SAR441000 when administered intratumorally. The study is estimated to conclude in February 2024.
Rising Incidences of Lung Cancer Support Market Growth
According to the World Health Organization (WHO) lung cancer is the leading cause of cancer related to deaths across the globe and smoking is the leading cause of lung cancer, resulting in approximately 85% of all cases. The growth of the smoking populace is one of the major factors bolstering the demand for lung cancer therapies. Current technologies provide two approaches for intratumoral therapy in lung cancer, namely percutaneous and bronchoscopic. Bronchoscopic approaches are more suitable for tumors that grow deeper in the lungs and are more likely to obstruct or crush larger airways whereas percutaneous approaches are used for treating peripheral lung tumors that are present near the chest wall. Various research activities are underway to evaluate the efficacy of bronchoscopic intratumoral injection. For instance, a team of researchers from Hiser Medical Center of Qingdao, Shandong, China is conducting a study to evaluate the adverse reactions and therapeutic effects of cisplatin and endostar in patients suffering from lung squamous cell carcinoma.
Checkpoint Inhibitors Account for Significant Market Share
Due to various benefits associated with checkpoint inhibitors, the segment is anticipated to account for a significant share of the market over the forecast period. Rising product approvals by different regulatory bodies including FDA is further supporting the segmental growth. In 2023, GlaxoSmithKline Pharmaceuticals Ltd. won the first PD-1 approval.
Jemperli was cleared as an add-on for patients undergoing chemotherapy with recurrent or primary advanced endometrial cancer. For being eligible for the therapy, the tumor of the patient must be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). In phase 3 RUBY trial, it was observed that the addition of Jemperli to chemotherapy reduced death or risk of progression by 72% among patients with mismatch repair deficient or microsatellite instability-high tumors, while showing a progression-free survival improvement of 24%.
Future Market Scenario (2024 – 2031F)
· Intratumoral immunotherapy is expected to bolster the effectiveness of cancer immunotherapies across a broad spectrum of malignancies. Addressing the barriers to intratumoral delivery can aid in maximizing the effectiveness of these therapies. Abundant opportunities are available to support the integration of novel biomaterials for providing sustained release and improved delivery of immunotherapies within tumors.
· With the help of continuous advancements towards the development of intratumoral drug-releasing interventional implants and devices that facilitate tumor approach, intratumoral nanoDDS administrations are expected to offer a suitable alternative to conventional systemic drug delivery.
Report Scope
“Intratumoral Cancer Therapies Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global intratumoral cancer therapies market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
|
Details |
|
|
Base Year of the Analysis |
2023 |
|
Historical Period |
2017-2022 |
|
Forecast Period |
2024-2031F |
|
Projected Growth Rate |
CAGR of 10.33% between 2024-2031F |
|
Revenue Forecast in 2031 |
USD 444.82 billion |
|
Segments Covered |
Type of Cancer, Technology, End-user |
|
Regions Covered |
North America, Europe, South America, Asia-Pacific, Middle East and Africa |
|
Key Companies Profiled |
Pfizer, Inc., F. Hoffmann-La Roche Ltd., Amgen Inc., Bayer AG, Bristol-Myers Squibb, Inc., Novartis AG, Sanofi SA, AstraZeneca, Inc., GlaxoSmithKline Pharmaceuticals Ltd., BioNTech SE |
|
Customization Scope |
15% free report customization with purchase |
|
Pricing and Purchase Options |
Avail the customized purchase options to fulfil your precise research needs |
|
Delivery Format |
PDF and Excel through email (subject to the license purchased) |
In this report, global intratumoral cancer therapies market has been segmented into the following categories:
· By Type of Cancer
o Breast Cancer
o Lung Cancer
o Colorectal Cancer
o Prostate Cancer
o Head and Neck Cancer
o Melanoma
o Others
· By Technology
o Vaccines
o Monoclonal Antibodies
o Cell Therapies
o Immunes System Modulator
o Adoptive Cell Transfer
o Checkpoint Inhibitors
o Cytokines
o Others
· By End-user
o Cancer Research Centers
o Specialty Clinics
o Hospitals
· By Region
o North America
o South America
o Europe
o Asia-Pacific
o Middle East & Africa
Key Players Landscape and Outlook
Key participants in the intratumoral cancer therapies market are GlaxoSmithKline Pharmaceuticals Ltd., BioNTech SE, Pfizer, Inc., F. Hoffmann-La Roche Ltd., and Amgen Inc. Increasing investments towards research and development activities and strategic collaborations are supporting the market expansion.
In 2023, BioNTech SE announced a partnership with the United Kingdom government to provide personalized mRNA cancer immunotherapies to up to 10,000 patients by 2030. The multi-year collaboration is expected to focus on cancer immunotherapies and the expansion of BioNTech’s footprint in the country. The company aims to roll out and design randomized clinical trials with the potential for registration for the personalized mRNA cancer immunotherapies provided by the company in the United Kingdom.
Key Players Operating in Global Intratumoral Cancer Therapies Market are:
· Pfizer, Inc.
· F. Hoffmann-La Roche Ltd.
· Amgen Inc.
· Bayer AG
· Bristol-Myers Squibb, Inc.
· Novartis AG
· Sanofi SA
· AstraZeneca, Inc.
· GlaxoSmithKline Pharmaceuticals Ltd.
· BioNTech SE
Markets and Data report answers the following questions:
· What is the current and future market size of the product/service in question globally or specific to different countries?
· How are the markets divided into different product/service segments and the market size and growth of each segment?
· What is the market potential of different product segments and their investment case?
· How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
· What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global intratumoral cancer therapies market, you may approach our team at info@marketsandata.com
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Intratumoral Cancer Therapies Market Outlook, 2017-2031F
4.1. Market Size & Forecast
4.1.1.By Value
4.1.2.By Volume
4.2. By Type of Cancer
4.2.1.Breast Cancer
4.2.2.Lung Cancer
4.2.3.Colorectal Cancer
4.2.4.Prostate Cancer
4.2.5.Head and Neck Cancer
4.2.6.Melanoma
4.2.7.Others
4.3. By Technology
4.3.1.Vaccines
4.3.2.Monoclonal Antibodies
4.3.3.Cell Therapies
4.3.4.Immunes System Modulator
4.3.5.Adoptive Cell Transfer
4.3.6.Checkpoint Inhibitors
4.3.7.Cytokines
4.3.8.Others
4.4. By End-user
4.4.1.Cancer Research Centers
4.4.2.Specialty Clinics
4.4.3.Hospitals
4.5. By Region
4.5.1.North America
4.5.2.South America
4.5.3.Europe
4.5.4.Asia-Pacific
4.5.5.Middle East & Africa
4.6. By Company Market Share (%), 2023
5. Global Intratumoral Cancer Therapies Market Outlook, By Region, 2017-2031F
5.1. North America*
5.1.1.Market Size & Forecast
5.1.1.1. By Value
5.1.1.2. By Volume
5.1.2.By Type of Cancer
5.1.2.1. Breast Cancer
5.1.2.2. Lung Cancer
5.1.2.3. Colorectal Cancer
5.1.2.4. Prostate Cancer
5.1.2.5. Head and Neck Cancer
5.1.2.6. Melanoma
5.1.2.7. Others
5.1.3.By Technology
5.1.3.1. Vaccines
5.1.3.2. Monoclonal Antibodies
5.1.3.3. Cell Therapies
5.1.3.4. Immunes System Modulator
5.1.3.5. Adoptive Cell Transfer
5.1.3.6. Checkpoint Inhibitors
5.1.3.7. Cytokines
5.1.3.8. Others
5.1.4.By End-user
5.1.4.1. Cancer Research Centers
5.1.4.2. Specialty Clinics
5.1.4.3. Hospitals
5.1.5.United States*
5.1.5.1. Market Size & Forecast
5.1.5.1.1. By Value
5.1.5.1.2. By Volume
5.1.5.2. By Type of Cancer
5.1.5.2.1. Breast Cancer
5.1.5.2.2. Lung Cancer
5.1.5.2.3. Colorectal Cancer
5.1.5.2.4. Prostate Cancer
5.1.5.2.5. Head and Neck Cancer
5.1.5.2.6. Melanoma
5.1.5.2.7. Others
5.1.5.3. By Technology
5.1.5.3.1. Vaccines
5.1.5.3.2. Monoclonal Antibodies
5.1.5.3.3. Cell Therapies
5.1.5.3.4. Immunes System Modulator
5.1.5.3.5. Adoptive Cell Transfer
5.1.5.3.6. Checkpoint Inhibitors
5.1.5.3.7. Cytokines
5.1.5.3.8. Others
5.1.5.4. By End-user
5.1.5.4.1. Cancer Research Centers
5.1.5.4.2. Specialty Clinics
5.1.5.4.3. Hospitals
5.1.6.Canada
5.1.7.Mexico
*All segments will be provided for all regions and countries covered
5.2. Europe
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.United Kingdom
5.2.5.Russia
5.2.6.Netherlands
5.2.7.Spain
5.2.8.Turkey
5.2.9.Poland
5.3. Asia-Pacific
5.3.1.India
5.3.2.China
5.3.3.Japan
5.3.4.Australia
5.3.5.Vietnam
5.3.6.South Korea
5.3.7.Indonesia
5.3.8.Philippines
5.4. South America
5.4.1.Brazil
5.4.2.Argentina
5.5. Middle East & Africa
5.5.1.Saudi Arabia
5.5.2.UAE
5.5.3.South Africa
6. Market Mapping, 2023
6.1. By Type of Cancer
6.2. By Technology
6.3. By End-user
6.4. By Region
7. Macro Environment and Industry Structure
7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
7.4.1. Political Factors
7.4.2. Economic System
7.4.3. Social Implications
7.4.4. Technological Advancements
7.4.5. Environmental Impacts
7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter’s Five Forces Analysis
7.5.1. Supplier Power
7.5.2. Buyer Power
7.5.3. Substitution Threat
7.5.4. Threat from New Entrant
7.5.5. Competitive Rivalry
8. Market Dynamics
8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
9.1. Patent Landscape
9.2. Regulatory Approvals
9.3. Innovations/Emerging Technologies
10. Key Players Landscape
10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
13.1. Pfizer, Inc.
13.1.1. Company Details
13.1.2. Key Management Personnel
13.1.3. Products & Services
13.1.4. Financials (As reported)
13.1.5. Key Market Focus & Geographical Presence
13.1.6. Recent Developments
13.2. F. Hoffmann-La Roche Ltd.
13.3. Amgen Inc.
13.4. Bayer AG
13.5. Bristol-Myers Squibb, Inc.
13.6. Novartis AG
13.7. Sanofi SA
13.8. AstraZeneca, Inc.
13.9. GlaxoSmithKline Pharmaceuticals Ltd.
13.10. BioNTech SE
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
14. Strategic Recommendations
15. About Us & Disclaimer
List of Figures
Figure 1. Global Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 2. Global Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 3. Global Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 4. Global Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 5. Global Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 6. Global Intratumoral Cancer Therapies Market Share (%), By Region, 2017-2031F
Figure 7. North America Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 8. North America Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 9. North America Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 10. North America Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 11. North America Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 12. North America Intratumoral Cancer Therapies Market Share (%), By Country, 2017-2031F
Figure 13. United States Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 14. United States Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 15. United States Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 16. United States Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 17. United States Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 18. Canada Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 19. Canada Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 20. Canada Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 21. Canada Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 22. Canada Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 23. Mexico Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 24. Mexico Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 25. Mexico Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 26. Mexico Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 27. Mexico Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 28. Europe Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 29. Europe Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 30. Europe Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 31. Europe Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 32. Europe Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 33. Europe Intratumoral Cancer Therapies Market Share (%), By Country, 2017-2031F
Figure 34. Germany Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 35. Germany Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 36. Germany Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 37. Germany Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 38. Germany Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 39. France Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 40. France Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 41. France Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 42. France Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 43. France Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 44. Italy Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 45. Italy Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 46. Italy Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 47. Italy Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 48. Italy Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 49. United Kingdom Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 50. United Kingdom Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 51. United Kingdom Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 52. United Kingdom Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 53. United Kingdom Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 54. Russia Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 55. Russia Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 56. Russia Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 57. Russia Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 58. Russia Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 59. Netherlands Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 60. Netherlands Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 61. Netherlands Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 62. Netherlands Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 63. Netherlands Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 64. Spain Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 65. Spain Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 66. Spain Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 67. Spain Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 68. Spain Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 69. Turkey Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 70. Turkey Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 71. Turkey Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 72. Turkey Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 73. Turkey Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 74. Poland Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 75. Poland Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 76. Poland Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 77. Poland Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 78. Poland Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 79. South America Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 80. South America Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 81. South America Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 82. South America Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 83. South America Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 84. South America Intratumoral Cancer Therapies Market Share (%), By Country, 2017-2031F
Figure 85. Brazil Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 86. Brazil Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 87. Brazil Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 88. Brazil Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 89. Brazil Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 90. Argentina Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 91. Argentina Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 92. Argentina Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 93. Argentina Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 94. Argentina Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 95. Asia-Pacific Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 96. Asia-Pacific Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 97. Asia-Pacific Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 98. Asia-Pacific Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 99. Asia-Pacific Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 100. Asia-Pacific Intratumoral Cancer Therapies Market Share (%), By Country, 2017-2031F
Figure 101. India Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 102. India Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 103. India Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 104. India Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 105. India Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 106. China Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 107. China Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 108. China Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 109. China Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 110. China Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 111. Japan Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 112. Japan Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 113. Japan Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 114. Japan Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 115. Japan Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 116. Australia Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 117. Australia Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 118. Australia Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 119. Australia Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 120. Australia Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 121. Vietnam Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 122. Vietnam Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 123. Vietnam Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 124. Vietnam Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 125. Vietnam Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 126. South Korea Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 127. South Korea Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 128. South Korea Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 129. South Korea Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 130. South Korea Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 131. Indonesia Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 132. Indonesia Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 133. Indonesia Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 134. Indonesia Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 135. Indonesia Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 136. Philippines Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 137. Philippines Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 138. Philippines Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 139. Philippines Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 140. Philippines Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 141. Middle East & Africa Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 142. Middle East & Africa Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 143. Middle East & Africa Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 144. Middle East & Africa Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 145. Middle East & Africa Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 146. Middle East & Africa Intratumoral Cancer Therapies Market Share (%), By Country, 2017-2031F
Figure 147. Saudi Arabia Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 148. Saudi Arabia Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 149. Saudi Arabia Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 150. Saudi Arabia Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 151. Saudi Arabia Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 152. UAE Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 153. UAE Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 154. UAE Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 155. UAE Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 156. UAE Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 157. South Africa Intratumoral Cancer Therapies Market, By Value, in USD Billion, 2017-2031F
Figure 158. South Africa Intratumoral Cancer Therapies Market, By Volume, in Million Units, 2017-2031F
Figure 159. South Africa Intratumoral Cancer Therapies Market Share (%), By Type of Cancer, 2017-2031F
Figure 160. South Africa Intratumoral Cancer Therapies Market Share (%), By Technology, 2017-2031F
Figure 161. South Africa Intratumoral Cancer Therapies Market Share (%), By End-user, 2017-2031F
Figure 162. By Type of Cancer Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
List of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
What regions are covered in the final report of global intratumoral cancer therapies market?
What are the major factors influencing the growth of global intratumoral cancer therapies market?
Who are the key players operating in global intratumoral cancer therapies market?
What is the market size and growth rate of global intratumoral cancer therapies market?
See Related Reports
Global Software as a Service Market Assessment Opportunities and Forecast, 2017-2031F
Global software as a service market is projected to witness a CAGR of 18.45% during the forecast period 2024-2031, growing from USD 208.1 billion in 2023 to USD 806.4 billion in 2031F. ....Read More
Published on
April 2024
4,500
Global All-Terrain Vehicle Tire Market Assessment Opportunities and Forecast, 2017-2031F
The global all-terrain vehicle tire market is projected to witness a CAGR of 7.43% during the forecast period 2024-2031, growing from USD 551.3 million in 2023 to USD 978.12 million in 2031. ....Read More
Published on
April 2024
4,500
Global Automotive Exhaust Systems Market Assessment Opportunities and Forecast, 2017-2031F
The global automotive exhaust systems market is projected to witness a CAGR of 7.97% during the forecast period 2024-2031, growing from USD 46.04 billion in 2023 to USD 85.03 billion in 2031. ....Read More
Published on
April 2024
4,500
Global Automotive Smart Display Market Assessment Opportunities and Forecast, 2017-2031F
The global automotive smart display market is projected to witness a CAGR of 8.48% during the forecast period 2024-2031, growing from USD 11.1 billion in 2023 to USD 21.29 billion in 2031. ....Read More
Published on
April 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
